Paul Rachlin is a Consultant in the Corporate Department, a member of the Private Equity Group, and a leader in the Life Sciences Group, resident in the New York office. He has over 20 years of experience in mergers and acquisitions and finance, representing clients in a broad range of transactions and industries.
Paul has unique experience representing medical device companies, from their formative stages through later stage financings, and has helped to navigate these companies through broad ranging strategic alternatives. He brings a highly multidisciplinary approach to the representation of emerging technology companies, and is experienced in guiding companies and investors in facing the myriad issues and pitfalls awaiting companies developing and commercializing new technologies.
An experienced securities lawyer, Paul has represented underwriters and U.S. and non-U.S. issuers in private placements, 144A offerings, Regulation S offerings, and initial and secondary public equity offerings in the U.S. and abroad. He also has many years of experience representing underwriters and issuers in connection with Israeli-based technology companies.
Today, Paul is among the leading U.S. attorneys representing Israeli technology companies, U.S. and European investors in Israeli companies, and the technologies developed by Israeli companies. He has traveled to Israel over 50 times during his more than 15 years of experience there, and maintains a continuing network of clients and contacts in this highly productive market for new technology companies.
Paul’s recent transactions, carried out with a team of highly skilled Proskauer lawyers, include the representation of:
TransPharma Medical Ltd., an Israeli based company developing an innovative transdermal drug delivery system, in its exclusive license agreement of TransPharma’s ViaDerm-hPTH (1-34) product to Eli Lilly and Company
Discotech Medical Technologies Ltd., an Israeli based medical device company, and its shareholders in the sale of its spine products business to Kyphon Inc. and DePuy Orthopedics, Inc. (a subsidiary of Johnson & Johnson) in combined transactions valued at over $240 million
WFD Ventures LLC and its shareholders in the sale of Hand Innovations LLC, an orthopedic medical device company, to DePuy Orthopedics, Inc., a subsidiary of Johnson & Johnson